Happy Monday, Zingernation! The 2014 Cadillac and McDonald’s breakfast sandwiches speak for themselves: Warren Buffett has a career full of great ideas, investment-related or otherwise. But this just might be his best idea yet. (Hint: you wouldn’t have to pay a dime in federal taxes if it happened.)

–Aaron Bry and Nic Chahine

Today’s Price Action:

$SPY: +1.03%
$QQQ: +1.10%
$DIA: +.43%

Plus, meet the company hoping to provide solutions for the 24 million Americans affected by Alzheimer’s.

And, did someone forward you this email? Click here to subscribe to this Benzinga newsletter and more.

TODAY’S MOST VOLATILE STOCKS

TODAY’S TOP STORY

Palantir Q1 Earnings: Revenue Beat And Raise

Briefly: Palantir reported first-quarter financial results after the market close today. Shares went higher initially, before selling off below levels of Friday’s close.

So Basically: Palantir said first-quarter revenue increased 21% year-over-year to $634 million, which beat the consensus estimate of $625.431 million.

So Then: Palantir's customer count grew 42% year-over-year and 11% on a quarter-over-quarter basis. Palantir ended the quarter with cash, equivalents and short-term U.S. treasury securities of $3.9 billion.

So What? Palantir — named after indestructible crystal balls from The Lord of the Rings — fittingly raised its full-year 2024 guidance. Palantir now sees full-year revenue in the range of $2.677 billion to $2.689 billion.

Click here to read more.

PRESENTED BY IGC PHARMA

IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact of Alzheimer’s disease makes it a major healthcare challenge. 

IGC Pharma (AMEX: IGC) is one of the companies hoping to provide solutions for millions of suffering Americans. It is a pharmaceutical company focused on developing innovative therapies for various medical conditions and fields, including Alzheimer's disease, chronic pain and women’s health. The company specializes in advanced formulas and the company’s lead drug candidate is IGC-AD1.

Click here to read more!

FIVE MOVERS

Lucid shares dropped after the close following the electric vehicle company’s earnings report failed to impress investors.

Symbiotic shares moved lower after the robotics company missed the Street’s EPS expectations.

HIMS reported strong earnings and guidance, sending the telehealth company higher in the afternoon session.

Disney shares moved higher as investors appeared to take bullish positions on the entertainment giant ahead of its earnings report.

Reddit shares moved higher today after the close as the social media stock received some love from analysts at JPM and BofA.

ONE TRADE IDEA FOR TOMORROW

Intel, Micron Among Winners In Biden's $280B CHIPS Act

Briefly: The Biden administration aims to leverage the $280 billion CHIPS and Science Act to attract semiconductor companies focusing on digital twins, virtual representations of physical chips.

So Basically: The initiative establishes the CHIPS Manufacturing USA institute, which seeks to create regional networks for collaboration and resource-sharing among companies developing both physical semiconductors and their digital twins.

So Then: Digital twins enable easier simulation of chip behavior, aiding in testing new processors before production. “Digital twin technology can help to spark innovation in research, development and manufacturing of semiconductors across the country," said Commerce Secretary Gina Raimondo.

So What? Key players such as Intel and Micron are poised to receive government funding under the CHIPS Act. The administration aims to incentivize semiconductor companies, particularly in developing new processor types, amid rising demand driven by advancements like AI.

Click here to read more.

PRESENTED BY IGC PHARMA

IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact of Alzheimer’s disease makes it a major healthcare challenge. 

IGC Pharma (AMEX: IGC) is one of the companies hoping to provide solutions for millions of suffering Americans. It is a pharmaceutical company focused on developing innovative therapies for various medical conditions and fields, including Alzheimer's disease, chronic pain and women’s health. The company specializes in advanced formulas and the company’s lead drug candidate is IGC-AD1.

Click here to read more!